In our quest to identify inhibitors of the eukaryotic translation initiation factor 4F (eIF4F), we serendipitously discovered a novel cytotoxic agent. Even though this compound did not inhibit translation, we explored the structural requirements for its cytotoxicity due to its structural originality. A series of 1,3-disubstituted iminobenzimidazoles was synthesized and evaluated for their in vitro cytotoxicity. The structure-activity relationship studies demonstrate that hydrophobic substituent is essential for activity. The most active compounds displayed a cytotoxicity in KB, HL60 and HCT116 human cancer cells with an IC 50 of about 1μM. These first-in-class series of low molecular weight synthetic molecules may provide the basis for the development of new anticancer drugs.
INTRODUCTION
Targeting the eukaryotic translation initiation factor 4F (eIF4F) holds promise as novel anticancer drugs that can overcome intra-tumor heterogeneity [1] . Indeed, the eIF4F complex, which regulates the cap-dependent protein synthesis is dysregulated in many types of cancers, leading to the overexpression of proteins that promote tumor growth, metastasis and resistance to cancer treatments. More important, several natural products that inhibit eIF4F, principally flavaglines, but also hippuristanol and pateamine, have demonstrated promising activities in several mouse models of cancers. In our quest to identify novel eIF4F inhibitors [2 -6] , we performed a virtual screening and we identified the iminobenzimidazole 1 (ChemBridge 5657657, Scheme 1). as a putative eIF4F inhibitor. Unfortunately, when we examine whether it inhibits eIF4F by using a bicistronic luciferase reporter construct [3] , we didn't find any significant activity. However, we found that it is cytotoxic in A375 melanoma cells. Considering that 1 had been described in a small number of patents and articles, none of them were related to cancer [7 -10] , and since the anticancer potential of iminobenzimidazoles has been scarcely investigated [11] , we explored the requirement of 1 for its cytotoxicity to determine whether it could provide the basis for the development of new anticancer agents.
MATERIALS & METHODS

Chemical Syntheses
2-[(4-Chlorophenoxy) Methyl] Oxirane (3)
4-Chlorophenol (12.0 g, 93.3 mmol, 1 equiv) was taken up into acetone (250 mL), then K 2 CO 3 (38.7 g, 280.0 mmol, 3 equiv) and epichlorohydrin (21.6 mL, 280.0 mmol, 3 equiv) were added consecutively. The reaction mixture was set to stir at reflux for 24 h. At this time, an additional 3 equiv of epichlorohydrin was added and the solution was allowed to stir at reflux for an additional 24 h. The mixture was cooled down to room temperature, and the solids were filtered off. The solvent was removed under reduced pressure and the resulting oil was taken up in diethyl ether (150 mL). The organic layer was washed with H 2 O (1 x 150 mL), 1M aqueous NaOH solution (1 x 150 mL), and brine (1 x 150 mL). The organic layer was dried over MgSO 4 (4) . To a solution of 2-aminobenzimidazole 2 (4.0 g, 30.04 mmol) in H 2 O/Dioxane 35/35 mL, KOH (1.6 g, 30.04 mmol) and oxirane 3 (5.5 g, 30.04 mmol) were added. The mixture was stirred at 110 °C for 2 hours, then cooled to room temperature. Dioxane was removed under reduced pressure and the resulting solution was extracted 3 times with 50 mL of AcOEt. The organic layer was dried over MgSO 4 , filtered, and the solvent was removed under reduced pressure. The resulting solid was recrystallized with EtOH/H 2 O 3/7 to give the desired product as a white solid (6.0 g, 18.7 mmol, 63%). 1 To a solution of 4 (0.1 g, 0.31 mmol) in acetonitrile (4 mL), 3-bromo-N,N-dimethylpropanamide 5 (0.08 g, 0.43 mmol) was added and the mixture was stirred at reflux for 15 hours. K 2 CO 3 (0.63 mmol) was added and the mixture was stirred at reflux for 2 days. Water (10 mL) and AcOEt (10mL) were added and the organic layer was extracted, dried over MgSO 4 and concentrated. The residue was purified on flash chromatographic using (MeOH/DCM 5/95) to give the desired product as a white solid (0.7 mg, 55% A mixture of 2 (0.1g, 0.31 mmol, 1 equiv) was taken up into 4 ml of acetonitrile, then bromoacetyl bromide 7 (0.02 mL, 0.31 mmol, 1equiv) and K 2 CO 3 (0.08 g, 0.62 mmol, 2 equiv). The reaction mixture was stirred at reflux for 24 h, the mixture was cooled down to room temperature, and the solid was filtered, to yield the desired product as a white solid (0.126 g, 39%); 1 
1-(4-Chlorophenoxy)-3-(2-Imino-2,3-Dihydro-1H-Benzo[d]imidazol-1-yl)Propan-2-ol (4)
(4-Chlorophenoxy)-3-(2-imino-2,3-dihydro-1H-benzo[d]imidazol-1-yl)propan-2-ol
1-(4-Chlorophenoxy)-3-(3-(2-Hydroxyethyl)-2-Imino-2,3-Dihydro-1H-Benzo[d] Imidazol-1-yl) Propan-2-ol (9b).
A mixture of 4 (0.1 g, 0.31 mmol, 1 equiv) was taken up into 4 ml of acetonitrile then 2-chloroethanol was added (0.04 mL, 0.62 mmol, 2.0 equiv). The reaction mixture was stirred at reflux for 24 h, the mixture was cooled down to room temperature. The solid was filtered, to yield the desired product as a white solid (0.04 g, 32%); 1 
2-[3-[3-(4-Chlorophenoxy)-2-Hydroxypropyl]-2-Imino-2,3-Dihydro-1H-Benzo[d] Imidazol-1-yl] Acetamide (9b)
A mixture of 4 (0.08 g, 0.25 mmol, 1 equiv) was taken up into 4 ml of acetonitrile, then chloroacetamide (0.02 mL, 0.25 mmol, 1.0 equiv) was added. The reaction mixture was stirred at reflux for 24 h, the mixture was cooled down to room temperature. The solid was filtered, to yield the desired product as a white solid (0.03 g, 31%); 1 
[3-[2-[1, 3-Dioxolan-2-yl) Ethyl]-2-Imino-2, 3-Dihydro-1H-Benzo[d] Imidazol-1-yl]-3-(4-Chlorophenoxy) Propan-2-ol (9c)
A mixture of 4 (0.2 g, 0.63 mmol, 1 equiv) was taken up into 4 ml of acetonitrile, then 2-(2-bromoethyl-1,3 dioxane) (0.12 g, 0.69 mmol, 1.1 equiv) was added. The reaction mixture was stirred at reflux for 24 h, the mixture was cooled down to room temperature, and the solid was filtered and purified by column chromatography (AcOEt:MeOH / 9: 1), to yield the desired product as a brown solid (0.1 g, 38%); 1 
1-(3-Allyl-2-Imino-2,3-Dihydro-1H-Benzo[d] Imidazol-1-yl)-3-(4-Chlorophenoxy)propan-2-ol (9d)
A mixture of 4 (0.12 g, 0.40 mmol, 1 equiv) was taken up into 4 ml of acetonitrile, then allylbromide (0.03 mL, 0.3 mmol, 1.0 equiv) was added. The reaction mixture was stirred at reflux for 24 h, the mixture was cooled down to room temperature, and the solid was filtered to yield the desired product as a white solid (0.05 g, 48%); 1 
1-(3-Benzyl-2-imino-2,3-Dihydro-1H-Benzo[d] Imidazol-1-yl)-3-(4-Chlorophenoxy)propan-2-ol (9e)
A mixture of 4 (0.09 g, 0.30 mmol, 1 equiv) was taken up into 4 ml of acetonitrile, then benzylbromide (0.05 g, 0.3 mmol, 1.0 equiv) was added. The reaction mixture was stirred at reflux for 24 h, the mixture was cooled down to room temperature, and the solid was filtered to yield the desired product as a white solid (0.06 g, 61%); 1 A mixture of 4 (0.2g, 0.63 mmol, 1 equiv) was taken up into 4 ml of acetonitrile, then 1-bromo-2-cyclohexyl ethane (0.132g, 0.69 mmol, 1.1 equiv) was added. The reaction mixture was stirred at reflux for 24 h, the mixture was cooled down to room temperature, and the solid was filtered, to yield the desired product as a white solid (0.126 g, 39%); 1 
(E)-1-(4-Chlorophenoxy)-3-(2-Imino-3-(3-Phenylallyl)-2,3-Dihydro-1H-Benzo[d] Imidazol-1-yl)-Propan-2-ol (9h)
A mixture of 4 (0.2 g, 0.63 mmol, 1 equiv) was taken up into 4 ml of acetonitrile, then 3-bromo-1phenyl-1-propene (0.137g, 0.69 mmol, 1.1 equiv)) was added. The reaction mixture was stirred at reflux for 24 h, the mixture was cooled down to room temperature, and the solid was filtered, to yield the desired product as a white solid (0.186 g, 58%); 1 
1-(4-Chlorophenoxy)-3-(2-Imino-3-(3-Phenylprop-2-yn-1-yl)-2,3-Dihydro-1H-Benzo [d] Imidazol-1-yl) Propan-2-ol (9i)
A mixture of 4 (0.15 g, 0.47mmol, 1 equiv) was taken up into 4 ml of acetonitrile, then 3-chloro-1phenyl-1-propyne (0.077 g, 0.51 mmol, 1.1 equiv) was added. The reaction mixture was stirred at reflux for 24 h and cooled down to room temperature. The solid was filtered to yield the desired product as a white solid (0.143 g, 66%); 1 
1-(4-Chlorophenoxy)-3-(2-Imino-3-(2-Phenoxyethyl)-2,3-Dihydro-1H-Benzo[d] Imidazol-1-yl) Propan-2-ol (9j)
A mixture of 4 (0.2 g, 0.63 mmol, 1 equiv) was taken up into 4 ml of acetonitrile, then 2-phenoxyethyl bromide (0.138 g, 0.69 mmol, 1.1 equiv) was added. The reaction mixture was stirred at reflux for 24 h and cooled down to room temperature. The solid was filtered to yield the desired product as a white solid (0.27 g, 85%); 1 
1-(3-(4-Bromophenethyl)-2-Imino-2,3-Dihydro-1H-Benzo[d] Imidazol-1-yl)-3-(4-Chlorophenoxy) Propan-2-ol (9k)
A mixture of 4 (0.2 g, 0.63 mmol, 1 equiv) was taken up into 4 ml of acetonitrile, then 1-bromoethyl -4-(2-bromoethylbenzene) (0.18 g, 0.69 mmol, 1.1 equiv) was added. The reaction mixture was stirred at reflux for 24 h and cooled down to room temperature. The solid was filtered to yield the desired product as a white solid (0.144 g, 46%); 1 
1-(4-Chlorophenoxy)-3-(3-(3,3-Diphenylpropyl)-2-Imino-2,3-Dihydro-1H-Benzo [d] Imidazol-1-yl) Propan-2-ol (9m)
A mixture of 4 (0.2g, 0.63 mmol, 1 equiv) was taken up into 4 ml of acetonitrile, then 3,3-diphenyl-1-bromopropane (0.18 g, 0.69 mmol, 1.1 equiv) was added. The reaction mixture was stirred at reflux for 24 h and cooled down to room temperature. The solid was filtered to yield the desired product as a white solid (0.37 g, 86%); 1 
N-Methyl-3-Nitropyridin-2-Amine (11)
To a solution of methylamine (10 mL, 80.7 mmol) at 0°C, 2-chloro-3-nitropyridine 10 (1.6 g, 10.0 mmol) was added in several portions. The solution was stirred 1 hour at 0°C then 2 hours at room temperature before concentration in vacuum. The residue was washed with water (20 mL) and then extracted 3 times in AcOEt (20 mL). The organic layer was dried over MgSO 4 then concentrated to give the desired product as a yellow oil (1.3 g, 85%) . 1 
N-Methylpyridine-2,3-Diamine (12)
To a solution of 11 (1.1 g, 7.18 mmol) in dry MeOH (25 mL), palladium 10% carbon (0.07 g, 0.71 mmol) was added. The mixture was stirred at room temperature and under hydrogen (atmospheric pressure) overnight. The solution was filtered over celite then concentrated to give the desired product as a yellow oil (0.88 g, 99%). To solution of 12 (0.6 g, 4.87 mmol) in MeOH/H 2 O 12/12 mL, cyanogen bromide (1.5 g, 14.63 mmol) was added. The mixture was stirred at 60°C for 4 hours. After cooling to room temperature, MeOH was evaporated and the solution was basified to pH 8 using a solution of NaOH 1N. The organic layer was extracted 3 times with AcOEt (20 mL), dried over MgSO4 and concentrated in vacuum. The residue was purified by flash chromatographic (MeOH/DCM 1/9) to give the desired product as a brown solid (0.37 g, 55% To a solution of 3-methyl-3H-imidazo [4,5-b] pyridin-2-amine (0.1 g, 0.67 mmol) in H 2 O/dioxane 3/3 mL, KOH (0.04 g, 0.67 mmol) and epoxide 3 (0.13 g, 0.74 mmol) were added. The mixture was stirred at 110 °C for 2 hours, then cooled down to room temperature. Dioxane was removed under reduced pressure and the resulting solution was extracted 3 times with 50 mL of AcOEt. The organic layer was dried over MgSO 4 , filtered, and the solvent was removed under reduced pressure. The resulting solid was recrystallized with EtOH/H 2 O 3/7 to give the desired product as a white solid (0.05 g, 0.16 mmol, 25%). 1 
Biological Assays
Cell Culture
The human cell lines KB (nasopharyngeal epidermis carcinoma) and HCT116 (colon adenocarcinoma) were purchased from ECACC (Salisbury, UK) and HL60 (promyeocytic leukaemia) cells from ATCC. KB cells were grown in D-MEM medium supplemented with 10% fetal calf serum, in the presence of penicillin, streptomycin and fungizone in a 75 cm 2 flask under 5% CO 2 , whereas the two other cell lines were grown in complete RPMI medium.
Scheme (1).
Structure of hit 1 and synthesis of its analogues 6, 8 and 9a-p.
Aza-isostere 14 was prepared in 4 steps starting from 2-chloro-3-nitropyridine 10 Scheme. (2) . Condensation with methylamine, followed by a reduction of the nitro group and ring closure with cyanogen bromide afforded the azabenzimidazole 13 that was alkylated by epoxide 3 to yield 14. Synthesis of aza-isostere 14.
Scheme (2). Synthesis of aza-isostere 14.
With the identification of potent cytotoxic compounds, we pursued our investigation by determining the IC 50 of newly synthesized compounds in 3 human cancer cell lines (Table 2), (Fig. 1) . These three human cancer cell lines are respectively derived from patients with cervical carcinoma, acute promyelocytic leukemia and colorectal carcinoma. As such, they represent a variety of different cancers. Replacement of the phenyl by a cyclohexyl (9g), introduction of unsaturations or an ether in the linker (9h-j), and the addition of a bromine (9k) or extra aromatic cycles (9l,m) did not significantly modified cytotoxicity, which was very similar in the 3 examined cell lines. These results suggest that these compounds probably bind with a comparable affinity for their target and indicate the requirement for a hydrophobic moiety connected to the benzimidazole ring by a linker with 2 or 3 carbons (Fig. 2) .
